NASDAQ:CARA
Cara Therapeutics Stock News
$0.87
+0.139 (+19.01%)
At Close: Mar 27, 2024
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
12:15pm, Friday, 25'th Feb 2022 GlobeNewswire Inc.
ST. GALLEN, Switzerland and STAMFORD, Conn., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
12:15pm, Friday, 25'th Feb 2022 GlobeNewswire
ST. GALLEN, Switzerland and STAMFORD, Conn., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Kapruvia ® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. The CHMP opinion is the basis for the European Commission’s final decision regarding marketing authorization for Kapruvia ® . If approved, Kapruvia ® will be the first therapy available in Europe for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients.
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
09:01pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
09:01pm, Tuesday, 22'nd Feb 2022 GlobeNewswire
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Tuesday, March 1, 2022, at 4:30 p.m. ET to report fourth quarter and full year 2021 financial results and provide a corporate update.
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
04:01pm, Tuesday, 22'nd Feb 2022
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of
Cara Therapeutics To Host Virtual R&D On March 11
03:06pm, Friday, 18'th Feb 2022 Benzinga
Cara Therapeutics, (NASDAQ:CARA) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on F
Cara Therapeutics To Host Virtual R&D On March 11
03:06pm, Friday, 18'th Feb 2022 Benzinga
Cara Therapeutics, (NASDAQ: CARA ) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on Friday, March 11 from 1:00 to 2:00 … Full story available on Benzinga.com
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
12:00pm, Friday, 18'th Feb 2022 GlobeNewswire Inc.
Presentation to highlight oral difelikefalin Phase 3 pruritus programs Presentation to highlight oral difelikefalin Phase 3 pruritus programs
Cara Therapeutics To Host Virtual R&D On March 11
10:06am, Friday, 18'th Feb 2022
Joana Goncalves, MD, chief medical officer of Cara Therapeutics Brian Kim, MD, MTR,
Earnings Preview: Cara Therapeutics (CARA) Q4 Earnings Expected to Decline
08:03pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium
04:19pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.
Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA
03:29pm, Monday, 14'th Feb 2022 Zacks Investment Research
Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.
Charles River (CRL) to Report Q4 Earnings: What's in Store?
04:09pm, Friday, 11'th Feb 2022 Zacks Investment Research
The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.
Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates
10:35pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Illumina (ILMN) delivered earnings and revenue surprises of 50% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
02:46pm, Wednesday, 09'th Feb 2022 Zacks Investment Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.